NEW YORK, Dec. 10 - Gene Logic said on Monday that GlaxoSmithKline has subscribed to its GeneExpress suite for an undislosed number of years, and will parter to create a new tissue database, the bioinformatics company said on Monday.
Terms of the deal call for the UK-based drug giant to access Gene Logic's BioExpress module, the largest data subset of the company's GeneExpress kit. In addition, the new database they plan to co-develop will contain segments of Glaxo's in-house data, which will be fully integrated with data from BioExpress.
Gene Logics' GeneExpress kit comprises gene expression and associated clinical information from tissues culled from normal and diseased human samples, model animal systems, and human and animal cell lines.
Terms of the deal were not disclosed.
"We look forward to providing enabling information products, based on our gene expression database, to help support [GlaxoSmithKline's] ongoing drug development and target discovery efforts," Mark D. Gessler, chairman and CEO of Gene Logic said.